Industri Jamu dan Farmasi Sido Muncul Tbk PT

The company maintains a strong liquidity position with a current ratio of 3.86, indicating that it has sufficient current assets to cover its current liabilities. The company's liquidity is further supported by a cash and equivalents balance of 7,365,000,000 IDR, which provides a buffer for short-term obligations. The company's debt-to-equity ratio is 0.0, suggesting that it is not leveraged and relies primarily on equity financing. In terms of profitability, the company demonstrates a return on equity (ROE) of 39.39% and a return on assets (ROA) of 33.39%, both of which are strong indicators of efficient use of equity and assets to generate profits. The company's operating income of 1,544,117,000,000 IDR and net income of 1,229,202,000,000 IDR reflect its ability to maintain profitability despite the competitive nature of the pharmaceutical industry. The company's revenue is primarily concentrated in Indonesia, with a significant portion derived from the domestic market. The company's exposure to geographic and segment-specific risks is limited, as it operates within a single primary market and product line. The company's revenue concentration in Indonesia may pose a risk if there are adverse changes in the domestic economic or regulatory environment. The company's growth trajectory is supported by its strong operating cash flow of 1,253,401,000,000 IDR and free cash flow of 179,570,000,000 IDR, which provide flexibility for reinvestment and expansion. The company's capital expenditure of -61,984,000,000 IDR indicates that it is not currently investing heavily in new assets, which may suggest a focus on maintaining existing operations rather than aggressive expansion. The company's risk assessment indicates a low level of liquidity and dilution risk, with no immediate filing-based flags detected. The company's low debt-to-equity ratio and strong cash reserves further support its low liquidity risk profile. The company's dilution risk is also low, as there are no indications of potential share dilution through new issuances or convertible instruments. Recent events and filings do not indicate any significant changes in the company's financial or operational status. The company's strong financial performance and low risk profile suggest that it is well-positioned to maintain its market position and continue generating value for shareholders.